Penghambatan Ekspresi Gen dengan Antisense Oligonukleotida sebagai Upaya Pengobatan Penyakit

  • Dian Ratih Laksmitawati Universitas Pancasila
  • Ani Retno Prijanti Fakultas Kedokteran Universitas Indonesia


Due to the development of biomolecular science eg. overexpression genes, genes that cause diseases can be identfied, Based on this fact, researchers developed a therapeutic strategy by inhibiting the gene expression using oligonucleotide antisense. Therapy using oligonucleotide antisense was based on a natural process of gene expression. Specific artificial antisense will match complementary with DNA and mRNA. By this process the transcription will stop. The effort of therapy is relatively new but a few have been carried out in the clinical trial phase. Obstacles are encountered in reaching the target cell by the oligonucleotide antisense.


1. Gewirtz AM, Sokol DL and Ratajczak MZ: Nucleic acid theraupetics: state of the art and future Prospects. Blood. 1998;92(3): 712-36.

2. Trent RJ. Molecular medicine : an introductory text for students. London: Churchill Livingstone; 1993.

3. Voet D and Voet JG. Biochemistry. 2nd Ed. USA: John Wiley and Sons Inc; 1995. p.915-1011.

4. Stryer L. Biochemistry. 4th Ed. New York: Freeman and Company; 1995.p.875-910

5. Tan TMC. Antisense nucleic acids – a rational approach for drug design. AsPac J Mol Biol.
Biotechnol. 1994; 2 (3): 166–173.

6. Szymkowski DE: Developing antisenseoligonucleotides from the laboratory to clinical trials.
Drug Discovery Today. 1996; 1: 415 – 28.

7. Myers KJ, Dean NM: Sensible use of antisense: how to use oligonucleotides as research tools. Trends in Pharmacological Science. 2000; 21: 19-23.

8. Gewirtz AM, Stein Cy A, Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci. 1996; 93: 3161 – 63.

9. Putnam DA. Antisense strategies and therapeutic applications. Am J Health Syst Pharm. 1996; 53 (2): 151–160.

10. Raha M, Wang G, Seidman MM, Glazer PM. Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosium variant. Proc Natl Acad Sci. 1996; 93: 2941.

11. Maher LJ 3rd. Prospects for the theurapetic use of antisense oligonucleotides. Cancer Invest. 1996; 14:1, 66-82.

12. Baserga R, Denhardt DT. Antisense strategies.Annals of the New York Academy of Science. 1992; 660:27 -35

13. Svinarchuk F, Bertrand JR, Malvy C. A short purine oligonucleotide forms a highly stable triple helix with the promoter of the murine c-pim-1 proto-oncogene. Nucleic Acids Res. 1994; 22: 3742.

14. Maine IP, Kodadek T. Efficient unwinding of triplex DNA by a DNA helicase. Biochem Biophys Res Commun. 1994; 204: 1119.

15. Lacoste J, Francois JC, Helene C. Triple helix formation with purine-rich phosporothioate containing oligonucleotides covalently linked to an acridine derivative. Nucleic Acids Res. 1997; 25: 1991.

16. Nellen W, Lichtenstein C. What makes an mRNA ant sense-itive? Trends Biochem Sci. 1993; 18:419.

17. Woolf T, Melton D, Jennings C. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci. 1992; 89: 7305.

18. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K. Molecular cloning of cDNA for double stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci. 1994; 91: 11457.

19. Pyle AM. Ribozymes: a distinct class of metalloenzymes. Science. 1993; 26: 709.

20. James HA, Gibson I. The theraupetic potential of ribozymes. Blood. 1998; 91:371.

21. Khan IM, Coulson JM. A novel method to stabilise antisense oligonucleotides againts exonuclease degradation. Nucleic Acids Res. 1993; 2: 2957.

22. Agrawal, S. Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology. 1996; 14: 376-87.

23. Soomets U, Hallbrink M, Langel U. Antisense properties of peptide nucleic acids. Front Biosci. 1999; 4 D: 782–86.
How to Cite
LAKSMITAWATI, Dian Ratih; PRIJANTI, Ani Retno. Penghambatan Ekspresi Gen dengan Antisense Oligonukleotida sebagai Upaya Pengobatan Penyakit. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 3, n. 2, p. 92-99, sep. 2005. ISSN 2614-6495. Available at: <>. Date accessed: 24 june 2024.